Collinsella aerofaciens as a predictive marker of response to probiotic treatment in non-constipated irritable bowel syndrome.

IF 12.2 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Gut Microbes Pub Date : 2024-01-01 Epub Date: 2024-01-04 DOI:10.1080/19490976.2023.2298246
Giorgio Gargari, Giacomo Mantegazza, Cesare Cremon, Valentina Taverniti, Alice Valenza, Maria Raffaella Barbaro, Giovanni Marasco, Robin Duncan, Walter Fiore, Roberto Ferrari, Valerio De Vitis, Giovanni Barbara, Simone Guglielmetti
{"title":"<i>Collinsella aerofaciens</i> as a predictive marker of response to probiotic treatment in non-constipated irritable bowel syndrome.","authors":"Giorgio Gargari, Giacomo Mantegazza, Cesare Cremon, Valentina Taverniti, Alice Valenza, Maria Raffaella Barbaro, Giovanni Marasco, Robin Duncan, Walter Fiore, Roberto Ferrari, Valerio De Vitis, Giovanni Barbara, Simone Guglielmetti","doi":"10.1080/19490976.2023.2298246","DOIUrl":null,"url":null,"abstract":"<p><p>Probiotics are exploited for adjuvant treatment in IBS, but reliable guidance for selecting the appropriate probiotic to adopt for different forms of IBS is lacking. We aimed to identify markers for recognizing non-constipated (NC) IBS patients that may show significant clinical improvements upon treatment with the probiotic strain <i>Lacticaseibacillus paracasei</i> DG (LDG). To this purpose, we performed a post-hoc analysis of samples collected during a multicenter, double-blind, parallel-group, placebo-controlled trial in which NC-IBS patients were randomized to receive at least 24 billion CFU LDG or placebo capsules <i>b.i.d</i>. for 12 weeks. The primary clinical endpoint was the composite response based on improved abdominal pain and fecal type. The fecal microbiome and serum markers of intestinal (PV1 and zonulin), liver, and kidney functions were investigated. We found that responders (R) in the probiotic arm (25%) differed from non-responders (NR) based on the abundance of 18 bacterial taxa, including the families <i>Coriobacteriaceae</i>, <i>Dorea</i> spp. and <i>Collinsella aerofaciens</i>, which were overrepresented in R patients. These taxa also distinguished R (but not NR) patients from healthy controls. Probiotic intervention significantly reduced the abundance of these bacteria in R, but not in NR. Analogous results emerged for <i>C. aerofaciens</i> from the analysis of data from a previous trial on IBS with the same probiotic. Finally, <i>C. aerofaciens</i> was positively correlated with the plasmalemmal vesicle associated protein-1 (PV-1) and the markers of liver function. In conclusion, LDG is effective on NC-IBS patients with NC-IBS with a greater abundance of potential pathobionts. Among these, <i>C. aerofaciens</i> has emerged as a potential predictor of probiotic efficacy.</p>","PeriodicalId":12909,"journal":{"name":"Gut Microbes","volume":"16 1","pages":"2298246"},"PeriodicalIF":12.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10773624/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut Microbes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19490976.2023.2298246","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Probiotics are exploited for adjuvant treatment in IBS, but reliable guidance for selecting the appropriate probiotic to adopt for different forms of IBS is lacking. We aimed to identify markers for recognizing non-constipated (NC) IBS patients that may show significant clinical improvements upon treatment with the probiotic strain Lacticaseibacillus paracasei DG (LDG). To this purpose, we performed a post-hoc analysis of samples collected during a multicenter, double-blind, parallel-group, placebo-controlled trial in which NC-IBS patients were randomized to receive at least 24 billion CFU LDG or placebo capsules b.i.d. for 12 weeks. The primary clinical endpoint was the composite response based on improved abdominal pain and fecal type. The fecal microbiome and serum markers of intestinal (PV1 and zonulin), liver, and kidney functions were investigated. We found that responders (R) in the probiotic arm (25%) differed from non-responders (NR) based on the abundance of 18 bacterial taxa, including the families Coriobacteriaceae, Dorea spp. and Collinsella aerofaciens, which were overrepresented in R patients. These taxa also distinguished R (but not NR) patients from healthy controls. Probiotic intervention significantly reduced the abundance of these bacteria in R, but not in NR. Analogous results emerged for C. aerofaciens from the analysis of data from a previous trial on IBS with the same probiotic. Finally, C. aerofaciens was positively correlated with the plasmalemmal vesicle associated protein-1 (PV-1) and the markers of liver function. In conclusion, LDG is effective on NC-IBS patients with NC-IBS with a greater abundance of potential pathobionts. Among these, C. aerofaciens has emerged as a potential predictor of probiotic efficacy.

作为非便秘性肠易激综合征患者对益生菌治疗反应的预测标志物的铜绿假丝酵母菌
益生菌可用于肠易激综合征的辅助治疗,但目前还缺乏针对不同形式肠易激综合征选择合适益生菌的可靠指导。我们的目的是找出识别非便秘(NC)肠易激综合征患者的标志物,这些患者在接受益生菌菌株副乳酸杆菌 DG(LDG)治疗后,临床症状可能会明显改善。为此,我们对一项多中心、双盲、平行组、安慰剂对照试验中收集的样本进行了事后分析,在该试验中,NC 肠易激综合征患者被随机分配到至少 240 亿 CFU LDG 或安慰剂胶囊中,每日服用 12 周。主要临床终点是基于腹痛和粪便类型改善的综合反应。我们对粪便微生物群以及肠道(PV1 和 zonulin)、肝脏和肾脏功能的血清标志物进行了调查。我们发现,益生菌组中的应答者(R)(25%)与非应答者(NR)在 18 个细菌类群的丰度上存在差异,其中包括 Coriobacteriaceae、Dorea spp.和 Collinsella aerofaciens 科,这些类群在 R 患者中的比例较高。这些分类群还将 R 型(而非 NR 型)患者与健康对照组区分开来。益生菌干预大大降低了这些细菌在 R 患者中的含量,但在 NR 患者中却没有。通过对之前使用同一种益生菌进行的肠易激综合征试验数据进行分析,也得出了类似的结果。最后,铜绿假单胞菌与质膜囊泡相关蛋白-1(PV-1)和肝功能指标呈正相关。总之,LDG 对潜在致病菌较多的 NC-IBS 患者有效。其中,C. aerofaciens已成为益生菌疗效的潜在预测因子。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gut Microbes
Gut Microbes Medicine-Microbiology (medical)
CiteScore
18.20
自引率
3.30%
发文量
196
审稿时长
10 weeks
期刊介绍: The intestinal microbiota plays a crucial role in human physiology, influencing various aspects of health and disease such as nutrition, obesity, brain function, allergic responses, immunity, inflammatory bowel disease, irritable bowel syndrome, cancer development, cardiac disease, liver disease, and more. Gut Microbes serves as a platform for showcasing and discussing state-of-the-art research related to the microorganisms present in the intestine. The journal emphasizes mechanistic and cause-and-effect studies. Additionally, it has a counterpart, Gut Microbes Reports, which places a greater focus on emerging topics and comparative and incremental studies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信